



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:

PCT/IB2012/051363

(22) International Filing Date:

22 March 2012 (22.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/471,758 5 April 2011 (05.04.2011) US

(71) Applicant (for all designated States except US): **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(72) Inventors; and

(75) **Inventors/Applicants (for US only): ANDREWS, Mark David** [GB/GB]; C/o Pfizer Global Research & Development Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **BAGAL, Sharanjeet Kaur** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **GIBSON, Karl Richard** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **OMOTO, Kiyoyuki** [JP/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **RYCKMANS, Thomas** [BE/GB]; C/o Pfizer Global Research & Development Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **SKERRATT, Sarah Elizabeth** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **STUPPLE, Paul Anthony**

[GB/GB]; C/o Pfizer Global Research & Development Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(74) Agent: **DROUIN, Stephane**; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES



(I)

(57) **Abstract:** The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.



-
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- Published:**
- *with international search report (Art. 21(3))*